Skip to content

Omeros OMER Net Investment in Lease

Net Investment in Lease at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
Immunome logo
ImmunomeIMNM
Vor Biopharma logo
Vor BiopharmaVOR
Annexon logo
AnnexonANNX
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$765.73M+307%
P/S8.5×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's net investment in lease?
Omeros (OMER) reported net investment in lease of $9.52M in Q1 2026.
How has Omeros's net investment in lease changed year-over-year?
Omeros's net investment in lease decreased by 31.8% year-over-year, from $13.95M to $9.52M.
What is the long-term trend for Omeros's net investment in lease?
Over 5 years (2020 to 2025), Omeros's net investment in lease has grown at a -15.9% compound annual growth rate (CAGR), from $25.53M to $10.71M.